Aileron Therapeutics
Our Company Pipeline Science Clinical Trials Investors & Media Careers
Contact
Our CompanyPipelineScienceClinical TrialsInvestors & MediaCareers
Aileron Therapeutics
Contact
Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas
Research ArticlesJamison WrightSeptember 26, 2017
Facebook0 Twitter Tumblr 0 Likes
Next

Stapled peptide reactivates p53

Review ArticlesJamison WrightMay 12, 2017
(617) 995-0900 info@aileronrx.com
Hours
Mon
Tue
Wed
Thu
Fri
Sat
Sun

Our CompanyAbout UsManagement TeamBoard of DirectorsAdvisory Board

PipelineALRN-6924Pipeline

ScienceStapled Peptide PlatformTargeting P53Preclinical ResearchScientific Publications

Clinical Trials

Investors & MediaNews ReleasesEvents & PresentationsStock InformationCorporate GovernanceSEC FilingsInvestor Resources

CareersJoin Our Team

Contact

Terms of Use

Privacy Policy

Aileron_Logo_4c.png

Aileron Therapeutics, Inc.
281 Albany Street
Cambridge, MA 02139

Phone: 617-995-0900
Fax: 617-995-2410
info@aileronrx.com

Copyright © 2017 Aileron Therapeutics, Inc. All rights reserved.